Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Fineline Cube Apr 2, 2026
Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026
Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Fineline Cube Apr 2, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Fineline Cube Apr 2, 2026
Company Drug

J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment

Fineline Cube Apr 8, 2025

The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...

Company Deals

TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China

Fineline Cube Apr 8, 2025

China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...

Company Drug

J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma

Fineline Cube Apr 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...

Policy / Regulatory

Shenzhen Unveils Comprehensive Policy Package to Boost Biopharma Innovation

Fineline Cube Apr 8, 2025

Shenzhen has launched an ambitious policy package, “Several Measures to Support Pharmaceuticals and Medical Devices...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA

Fineline Cube Apr 8, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...

Company Drug

SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study

Fineline Cube Apr 8, 2025

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...

Company Drug

Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau

Fineline Cube Apr 8, 2025

China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...

Company Drug

Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation

Fineline Cube Apr 8, 2025

China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...

Company Drug

Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion

Fineline Cube Apr 8, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...

Company Drug

Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors

Fineline Cube Apr 8, 2025

China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...

Policy / Regulatory

Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency

Fineline Cube Apr 8, 2025

The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...

Company Deals

Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China

Fineline Cube Apr 8, 2025

In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...

Company Deals

Siemens Set to Acquire Dotmatics for $5.1 Billion to Boost Life Sciences R&D

Fineline Cube Apr 8, 2025

German industrial giant Siemens AG (ETR: SIE) has announced plans to acquire US-based Dotmatics, a...

Company Deals

Lynmou Medical Secures Series A Funding for Endoscope Expansion

Fineline Cube Apr 8, 2025

Lynmou Medical, a Hangzhou-based provider of soft endoscope solutions, has reportedly secured “tens of millions”...

Company Drug

Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC

Fineline Cube Apr 8, 2025

Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...

Company Deals

Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction

Fineline Cube Apr 8, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with...

Company Drug

Suzhou Ribo Life Science Completes Enrollment for Phase IIa Study of FXI-Targeted siRNA Drug RBD4059

Fineline Cube Apr 8, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced the completion of subject enrollment for the...

Company Drug

Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA

Fineline Cube Apr 7, 2025

China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...

Company Drug

Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea

Fineline Cube Apr 7, 2025

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) has secured clinical trial approval from China’s National...

Company Deals

Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline

Fineline Cube Apr 7, 2025

China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial...

Posts pagination

1 … 161 162 163 … 645

Recent updates

  • RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
  • Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies
  • Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
  • NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.